Fused [d]pyridazin-7-ones

A compound of Formula (II):

• wherein:
• ring F is:
• R1 is selected from:
• (a) hydrogen, C1-C6 alkyl substituted with 0 to 3 R10 groups, C2-C6 alkenyl substituted with 0 to 3 R10 groups, C2-C6 alkynyl substituted with 0 to 3 R10 groups, C6-C12 aryl substituted with 0 to 3 R10 groups, C3-C7 cycloalkyl substituted with 0 to 3 R10 groups, C5-C10 heterocyclyl substituted with 0 to 3 R10 groups, C5-C10 heteroaryl substituted with 0 to 3 R10 groups;
• (b) halogen, —CF3, —CHF2, —C≡N, —CHO, —O(CRa2)nR8, —(CRa2)nC(═O)(CRa2)nR8, —(CRa2)nC(═O)(CRa2)nOR8, —(CRa2)nSi(R8)3, —(CRa2)nNO2—(CRa2)nN(Rb)(Rc), —(CRa2)nC(═O)N(Rb)(Rc), —(CRa2)nOC(═O)N(Rb)(Rc), —(CRa2)nOC(═O)(CRa2)nR8, —(CRa2)nN(Rb)C(═O)R8, —(CRa2)nNC(═O)N(Rb)(Rc), —(CRa2)nNC(═O)OR8, and —(CRa2)nNS(O)xR8;
• R4 is selected from hydrogen, halogen, C1-C4 alkyl, and —O(CRa2)nR8;
• R2 and R3 together form a methylenedioxy or an ethylenedioxy group;
• R5 is C5-C10 heteroaryl substituted with 0 to 3 R9 groups;
• R6 is hydrogen;
• R7 is selected from hydrogen and methyl;
• R8 is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C6-C12 aryl, C3-C7 cycloalkyl, C5-C10 heterocyclyl, and C5-C10 heteroaryl;
• R9 is selected from:
• (a) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C12 aryl, C3-C7 cycloalkyl, C5- C10 heterocyclyl, C5-C10 heteroaryl,
• (b) halogen, —CF3, —CHF2, —C≡N, —CHO,
• (c) —O(CRa2)nR8, —(CRa2)nC(═O)(CRa2)nR8, —(CRa2)nC(═O)(CRa2)nOR8, —(CRa2)nSi(R8)3, —(CRa2)nNO2, —(CRa2)nN(Rb)(Rc), —(CRa2)nC(═O)N(Rb)(Rc), —(CRa2)nOC(═O)N(Rb)(Rc), —(CRa2)nOC(═O)(CRa2)nR8, —(CRa2)nN(Rb)C(═O)R8, —(CRa2)nNC(═O)N(Rb)(Rc), —(CRa2)nNC(═O)OR8, and —(CRa2)nNS(O)xR8;
• R10 is selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, and —OR11;
• R11 is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C6-C12 aryl, C3-C7 cycloalkyl, C5-C10 heterocyclyl, and C5-C10 heteroaryl;
• Ra is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, and C2-C4 alkynyl;
• Rband Rc are independently selected from hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, and C2-C4 alkynyl;
• n is independently at each occurrence 0, 1, 2, 3 or 4;
• and
• x is independently 1 or 2.

A compound of Formula (II):

• wherein:
• ring F is:
• R1 and R2 are independently selected from:
• (a) hydrogen, C1-C6 alkyl substituted with 0 to 3 R10 groups, C2-C6 alkenyl substituted with 0 to 3 R10 groups, C2-C6 alkynyl substituted with 0 to 3 R10 groups, C6-C12 aryl substituted with 0 to 3 R10 groups, C3-C7 cycloalkyl substituted with 0 to 3 R10 groups, C5-C10 heterocyclyl substituted with 0 to 3 R10 groups, C5-C10 heteroaryl substituted with 0 to 3 R10 groups;
• (b) halogen, —CF3, —CHF2, —C≡N, —CHO, —O(CRa2)nR8, —(CRa2)nC(═O)(CRa2)nR8, —(CRa2)nC(═O)(CRa2)nOR8, —(CRa2)nSi(R8)3, —(CRa2)nNO2, —(CRa2)nN(Rb)(Rc), —(CRa2)nC(═O)N(Rb)(Rc), —(CRa2)nOC(═O)N(Rb)(Rc), —(CRa2)nOC(═O)(CRa2)nR8, —(CRa2)nN(Rb)C(═O)R8, —(CRa2)nNC(═O)N(Rb)(Rc), —(CRa2)nNC(═O)OR8, —(CRa2)nNS(O)xR8;
• and
• (c) a group wherein R1 and R2 together form a methylenedioxy or an ethylenedioxy group;
• R3 and R4 are independently selected from hydrogen, halogen, C1-C4 alkyl, and —O(CRa2)nR8;
• alternatively, R2 and R3 together form a methylenedioxy or an ethylenedioxy group;
• R5 is benzofuranyl substituted with 0 to 3 R9 groups;
• R6 is hydrogen;
• R7 is selected from hydrogen and methyl;
• R8 is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C6-C12 aryl, C3-C7 cycloalkyl, C5-C10 heterocyclyl, and C5-C10 heteroaryl;
• R9 is selected from:
• (a) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C12 aryl, C3-C7 cycloalkyl, C5-C10 heterocyclyl, C5-C10 heteroaryl,
• (b) halogen, —CF3, —CHF2, —C≡N, —CHO,
• (c) —O(CRa2)nR8, —(CRa2)nC(═O)(CRa2)nR8, —(CRa2)nC(═O)(CRa2)nOR8, —(CRa2)nSi(R8)3, —(CRa2)nNO2, —(CRa2)nN(Rb)(Rc), —(CRa2)nC(═O)N(Rb)(Rc), —(CRa2)nOC(═O)N(Rb)(Rc), —(CRa2)nOC(═O)(CRa2)nR8, —(CRa2)nN(Rb)C(═O)R8, —(CRa2)nNC(═O)N(Rb)(Rc), —(CRa2)nNC(═O)OR8, and —(CRa2)nNS(O)xR8;
• R10 is setected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, and —OR11;
• R11 is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C6-C12 aryl, C3-C7 cycloalkyl, C5=C10 heterocyclyl, and C5-C10 heteroaryl;
• Ra is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, and C2-C4 alkynyl;
• Rb and Rc are independently selected from hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, and C2-C4 alkynyl;
• n is independently at each occurrence 0, 1, 2, 3 or 4;
• and
• x is independently 1 or 2.

A compound as described in Table I:

• TABLE I
• Example
• R1
• R2
• R3
• R4
• R5
• R7
• 4b
• H
• H
• H
• H
• H
• 4c
• H
• H
• H
• H
• H
• 4d
• H
• H
• H
• H
• H
• 4e
• H
• H
• H
• H
• H
• 4f
• H
• H
• H
• H
• H
• 4g
• H
• H
• H
• H
• H
• 4h
• H
• H
• H
• H
• H
• 4i
• H
• H
• H
• H
• H
• 4j
• H
• H
• H
• H
• H
• 4k
• H
• H
• H
• H
• H
• 4l
• H
• —OCH3
• H
• H
• H
• 4m
• H
• —OCH2O—
• H
• H
• 4n
• BnO
• H
• H
• H
• H
• 4o
• H
• BnO
• H
• H
• H
• 4p
• H
• H
• BnO
• H
• H
• 4q
• H
• OH
• H
• H
• H
• 4r
• H
• H
• H
• H
• H
• 4s
• H
• H
• H
• H
• H
• 4t
• H
• H
• —OCH3
• H
• H
• 4u
• H
• H
• —OCH3
• H
• H
• 4v
• H
• —NO2
• H
• H
• H
• 11a
• H
• H
• H
• H
• —CH3
• 11b
• H
• H
• H
• H
• —CH3
• 11c
• H
• H
• H
• H
• —CH3
• or a stereoisomer or pharmaceutically acceptable salt form thereof

A compound as described in Table II:

• TABLE II
• Example
• R1
• R2
• R3
• R4
• R5
• R7
• 14b
• H
• H
• H
• H
• H
• 14c
• H
• H
• H
• H
• H
• 14e
• H
• H
• H
• H
• H
• or a stereoisomer or pharmaceutically acceptable salt form thereof.